The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...